Clinical trial NCT03119246: Beta Testing of a New Assessment in Huntington's Disease (HD)
Official title: Beta Testing of a New Assessment Protocol for Assessment of Complex Therapies in Huntington's Disease (HD)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Huntington Disease
Keywords: beta testing
assessment battery
HD
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: School of Biosciences - Cardiff University
name: University Hospital of Wales
name: National Reference Center for Huntington's disease Cognitive Neurology Unit
name: Institut National de la Santé Et de la Recherche Médicale, France
name: Manchester Centre for Genomic Medicine - St. Mary's Hospital University of Manchester
name: George-Huntington-Institut GmbH
First posted: 2017-04-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Huntington's disease (HD) is an inherited neurodegenerative disease for which there are no existing disease-modifying treatments.

Repair-HD is an EU FP7 consortium that aims to establish all the preclinical requirements for transplantation of stem cell-derived neurons in HD in order to replace those lost to the disease process. These requirements include the generation of new clinical assessments for detailed monitoring of patients with HD who have undergone cell replacement therapy.

This protocol describes the beta testing of a new clinical assessment battery: Core Assessment Protocol for Intrastriatal Transplantation in HD version 2 (CAPIT-HD beta / CAPIT-HD2). CAPIT-HD beta represents a substantial revision of a previous CAPIT-HD battery published over 20 years ago, which is in need of updating in order to accommodate knowledge from clinical transplant studies over this time and to take advantage of technological advances in patient assessment.

HD is a complex disorder in which there is relentless deterioration of motor, cognitive and behavioural functions, usually from mid-life onwards. The original CAPIT battery aimed to capture elements of change in all three domains, but was based predominantly on subjective semi-quantitative assessment tools that have poor inter-rater reliability. Moreover, a number of deficits, such as impairments in social cognition, were not recognised when the original CAPIT-HD battery was constructed, so we have developed novel assessments of these deficits, some of which are included in CAPIT-HD beta. The beta testing will take place in established HD clinical centres in Cardiff, Manchester, Paris, and Munster by teams of researchers who are experienced in leading clinic research in HD. Patients with early to moderate HD will be assessed at baseline, and at one and twelve months later, to assess the reliability and sensitivity of the CAPIT-HD beta battery. Arrangements for data storage and analysis are in place.


Eligibility criteria: 1. Patients Inclusion criteria

   * Must be confirmed to carry the HD gene through genetic testing (CAG ≥ 36)
   * Must be 18 years or above
   * Stage I or II disease (TFC staging)

   Exclusion criteria
   * The inability to approve consent
   * Any comorbid condition that has the potential to confound the results of the study
2. Controls Inclusion criteria - Must be 18 years or above

Exclusion criteria

* The inability to approve consent
* Any comorbid condition that has the potential to confound the results of the study

Primary outcomes:
measure: All dysfunction or disorder of huntington patient measured by means of a new battery assessments
timeFrame: 1 year
Secondary outcomes:
measure: Difference on motor score between patient and healthy volontary measured by motor tests of the revised Core Assessment Protocol
timeFrame: 1 year
measure: Difference on cognitive score between patient and healthy volontary measured by cognitive tests of the revised Core Assessment Protocol
timeFrame: 1 year
measure: Difference on psychiatric score between patient and healthy volontary measured by psychiatric evaluation of the revised Core Assessment Protocol
timeFrame: 1 year
measure: Difference on functional scale between patient and healthy volontary measured by functional evaluation of the revised Core Assessment Protocol
timeFrame: 1 year
measure: Number of new assessment battery performed correctly
timeFrame: 1 year
Other outcomes:
Locations:
city: Creteil
country: France
facility: Henri Mondor Hospital
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Anne-Catherine BACHOUD-LEVI, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: School of Biosciences - Cardiff University
name: Anne ROSSER, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Manchester Centre for Genomic Medicine - St. Mary's Hospital
name: David CRAUFURD, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: George-Huntington-Institut GmbH
name: Ralf REILMANN, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: